Automated, fast, and sensitive quantification of drugs human plasma by LC/LC-MS - Quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors

An analytic assay based on automated sample preparation and liquid chromatography (LC) coupled with electrospray mass spectrometry (ESI-MS) was developed for the quantification of 6 protease inhibitors (PIs) and 3 nonnucleoside reverse transcriptase inhibitors (NNRTIs). The 6 PIs, amprenavir, indinavir, ritonavir, lopinavir, nelfinavir, and saquinavir, as well as the three NNRTIs, nevirapine, efavirenz, and delavirdine, require a succinct analysi's technique for therapeutic drug monitoring in HIV/AIDS patients. After protein precipitation, samples were loaded on a C-8, 10 x 4-mm extraction column, washed, and, after activation of the column-switching valve, backflushed onto the 30 x 2.1 mm C-8 analytic column. [M+H](+) ions were detected in the selected ion mode. A nonlinear fit (y(-1) = a + b/x, all r(2) > 0.999) for amprenavir, indinavir, ritonavir, lopinavir, nelfinavir, and saquinavir and a linear fit (y = ax + b, all r(2) > 0.999) for nevirapine, efavirenz, and delavirdine led to best regression. Absolute recoveries were as follows: PIs > 81%; NNRTIs > 76%. Interday and intraday precision were < 12.5% for the Pis and < 11.7% for the NNRTIs. Interday and intraday accuracy were < 12.2% for the PIs and < 14.9% for the NNRTIs. Limits of quantification were 20, 40, 50, 40, 40, 20, and 100 mug/L for amprenavir, indinavir, ritonavir, lopinavir, nelfinavir, saquinavir, and the NNRTIs, respectively. The assay allows fast analysis of patient samples for therapeutic drug monitoring (TDM) and has successfully been used for TDM and pharmacokinetic drug-drug interactions studies.